Feb 6 2024 |
et al., Microbiology Spectrum, doi:10.1128/spectrum.02980-23 | SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir |
| 1% worse recovery (p=1) and 252% worse results (p=0.1). RCT 242 symptomatic outpatients showing no significant difference in viral clearance or symptom resolution with pomotrelvir treatment initiated within 5 days of symptom onset. Based on the description provided it is not clear why the numb.. | ||